NewslettersEndothelial Cell NewsOxurion Announces Top-Line Results from Part A of Phase II INTEGRAL Trial Evaluating THR-687 for Treatment of Diabetic Macular Edema (DME)By Danielle Corrigan - May 16, 20220192Oxurion NV announced top-line results from Part A of its Phase II trial of THR-687, an integrin antagonist, for the treatment of DME.[Oxurion NV]Press Release